Biopharmaceutical firm Immunomedics of Morris Plains, NJ, announced last month that the District Court in the Hague upheld the company's European patent when it dismissed a legal action brought by Hoffman LaRoche. Basil, Switzerland-based LaRoche filed
Biopharmaceutical firm Immunomedics of Morris Plains, NJ, announced last month that the District Court in the Hague upheld the company's European patent when it dismissed a legal action brought by Hoffman LaRoche. Basil, Switzerland-based LaRoche filed the action in response to an infringement suit Immunomedics brought against it last fall. Immunomedics' European patent is valid in nine countries and covers CEA-specific antibodies as well as immunoassays which use CEA antibodies, according to the company's patent attorney, Bernhard Saxe of Foley & Lardner in Washington, DC.
In other Immunomedics news, the company last month reported that it has conferred a royalty-bearing, nonexclusive license to Dako A/S of Glostrup, Denmark, for its worldwide patents covering antibodies to CEA. Dako will sell the antibodies to pathology laboratories that stain tumor specimens for CEA.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.